NervGen Pharma (TSE:NGEN) has released an update.
NervGen Pharma, a clinical-stage biotech company, is set to present at the Stifel 2024 Healthcare Conference, highlighting its innovative treatments for nervous system repair. The company’s lead molecule, NVG-291, is currently being tested for spinal cord injury, while a new candidate, NVG-300, is in preclinical evaluation for stroke and ALS.
For further insights into TSE:NGEN stock, check out TipRanks’ Stock Analysis page.
